How does harmine help with diabetes?

Harmine inhibits the DYRK1A enzyme, allowing pancreatic beta-cells to proliferate and regenerate. This increases the number of insulin-producing cells, potentially improving blood sugar control and diabetes management through enhanced insulin secretion capacity.

What is the difference between harmine and harmaline?

Both are beta-carboline alkaloids, but harmine has a methoxy group while harmaline has a methylenedioxy group in their chemical structure. Harmine specifically targets DYRK1A for beta-cell proliferation, while harmaline has different pharmacological properties and is primarily studied for its psychoactive effects.

Can harmine regenerate pancreatic cells damaged by diabetes?

Preclinical studies suggest harmine can promote proliferation of existing beta-cells rather than regenerating completely destroyed cells. The compound works best when some functional beta-cell mass remains, making it potentially more effective in type 2 diabetes or early-stage type 1 diabetes.

Is harmine safe to take with diabetes medications?

Harmine's interactions with diabetes medications are not well-studied in humans. Given its potential to affect blood sugar through beta-cell proliferation, it could theoretically enhance the effects of insulin or other glucose-lowering drugs, requiring careful medical supervision.

What foods contain harmine naturally?

Harmine is found in plants like Syrian rue (Peganum harmala), passion flower (Passiflora incarnata), and certain species of Banisteriopsis used in ayahuasca preparations. However, dietary sources contain variable and typically low concentrations compared to concentrated extracts used in research.

What is the current evidence quality for harmine's effects on pancreatic beta cells?

Most evidence for harmine's beta-cell benefits comes from preclinical and animal studies, which show promising results for DYRK1A inhibition and beta-cell proliferation. While these findings are compelling, human clinical trials remain limited, meaning efficacy and safety in humans have not yet been fully established. The sustained effects observed in animal models (lasting at least one month after treatment) suggest potential durability, but this requires confirmation in human populations.

Who should avoid taking harmine supplements?

Pregnant and nursing women should avoid harmine due to insufficient safety data in these populations. Individuals with existing liver conditions or those taking medications metabolized by the liver should consult a healthcare provider before supplementing, as harmine may affect hepatic enzyme activity. People with monoamine oxidase (MAO) inhibitor sensitivity or taking MAOI medications should exercise caution, as harmine is a beta-carboline alkaloid that may have MAOI-like properties.

How does harmine's mechanism differ when combined with GLP-1 receptor agonists versus taken alone?

When combined with GLP-1 receptor agonists, harmine enhances beta-cell expansion more effectively than either treatment alone, creating a synergistic effect that increases both beta-cell mass and function. Taken alone, harmine works primarily through DYRK1A inhibition to promote beta-cell proliferation, but the combination appears to provide superior and more sustained results. This synergistic relationship suggests harmine may be most beneficial as part of a multi-targeted approach rather than as monotherapy.

Harmine (Beta-carboline Alkaloid)

Harmine is a beta-carboline alkaloid that inhibits DYRK1A enzyme activity, promoting pancreatic beta-cell proliferation and regeneration. This compound shows promise for diabetes management by enhancing insulin-producing cell mass and function.

Category: Compound Evidence: 6/10 Tier: Emerging

Harmine (Beta-carboline Alkaloid) — Hermetica Encyclopedia

Origin & History

Harmine is a beta-carboline alkaloid naturally found in Peganum harmala (Syrian rue) and plants used in traditional ayahuasca preparations. It can be extracted from these plant sources or synthesized as pharmaceutical-grade material for clinical research applications.

Historical & Cultural Context

Harmine is found in plants traditionally used in ayahuasca preparations in South American indigenous medicine systems. However, specific traditional therapeutic applications and duration of historical use are not detailed in current research literature.

Health Benefits

• Promotes pancreatic beta-cell proliferation through DYRK1A inhibition, potentially beneficial for diabetes management (preclinical evidence)
• Enhances beta-cell mass and function when combined with GLP-1 receptor agonists, with effects sustained for at least one month after treatment cessation (animal studies)
• Demonstrates selective expansion of human beta cells without affecting other pancreatic cell types in 3-month safety studies (transplanted human islet models)
• Shows synergistic effects with exenatide in increasing both mass and function of human beta cells in diabetic mice models (preclinical evidence)
• No psychoactive or hallucinogenic effects observed at clinically tested doses in Phase 1 human trials (preliminary human evidence)

How It Works

Harmine inhibits dual-specificity tyrosine-regulated kinase 1A (DYRK1A), a key enzyme that normally suppresses beta-cell proliferation in the pancreas. By blocking DYRK1A activity, harmine removes the molecular brake on cell division, allowing adult pancreatic beta-cells to proliferate and regenerate. This mechanism synergizes with GLP-1 receptor agonists to enhance overall beta-cell mass and insulin secretion capacity.

Scientific Research

Mount Sinai researchers conducted a Phase 1 open-label trial in 25 healthy adults testing pure pharmaceutical-grade harmine, finding no psychoactive effects but dose-dependent gastrointestinal side effects. In July 2024, researchers published findings in Science Translational Medicine demonstrating harmine combined with exenatide increased human beta-cell mass and function in diabetic mice models, with effects lasting at least one month post-treatment.

Clinical Summary

Current evidence for harmine comes primarily from preclinical studies and cell culture experiments rather than human clinical trials. Laboratory studies demonstrate significant increases in beta-cell proliferation rates and improved glucose tolerance in animal models. Research shows that harmine combined with GLP-1 receptor agonists produces sustained effects lasting at least one month after treatment discontinuation. However, human safety and efficacy data remain limited, requiring further clinical investigation before therapeutic recommendations can be made.

Nutritional Profile

Harmine is a pure bioactive alkaloid compound (beta-carboline class), not a nutritional food ingredient, and therefore has no macronutrient, micronutrient, fiber, or caloric profile in the conventional dietary sense. As an isolated phytochemical, it is typically encountered in research or supplemental contexts at pharmacologically relevant doses. Key compositional facts: Molecular formula C13H12N2O, molecular weight 212.25 g/mol, naturally occurring as a crystalline solid. Found endogenously in plants such as Peganum harmala (Syrian rue) at concentrations of approximately 2–7% dry weight of seeds, and in Banisteriopsis caapi vine at approximately 0.31–8.43 mg/g dry weight. As a pure compound, it contains no vitamins, minerals, dietary fiber, or protein. Bioactive concentration in research contexts: in vitro studies use concentrations typically ranging from 1–10 μM; preclinical animal studies utilize doses in the range of 10–80 mg/kg body weight. Bioavailability notes: Harmine is lipophilic, readily crosses the blood-brain barrier, and is metabolized primarily via CYP1A2-mediated demethylation to harmol in the liver; oral bioavailability is moderate and subject to first-pass metabolism. It acts as a reversible inhibitor of monoamine oxidase A (MAO-A) and a potent DYRK1A kinase inhibitor at nanomolar concentrations (IC50 approximately 33–80 nM for DYRK1A).

Preparation & Dosage

Clinically studied ranges include: Phase 1 human trials used multiple ascending doses of pure pharmaceutical-grade harmine (specific doses not disclosed). Preclinical efficacy studies used 1-10 mg/kg daily for 7 days in mouse models, with improved analogs showing efficacy at 1 mg/kg. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

GLP-1 receptor agonists (exenatide, exendin-4), berberine, chromium picolinate, alpha-lipoic acid, cinnamon extract

Safety & Interactions

Harmine's safety profile in humans is not well-established due to limited clinical research. As a beta-carboline alkaloid structurally related to compounds with psychoactive properties, harmine may interact with medications affecting neurotransmitter systems, particularly MAO inhibitors and antidepressants. Potential side effects could include nausea, dizziness, and cardiovascular effects based on its chemical class. Pregnant and breastfeeding women should avoid harmine due to insufficient safety data.